You can use your existing Medical Independent, MediLearning or PharmacistCPD account to log in. is Ireland's only investigative medical news website for doctors, healthcare professionals and anyone with an interest in health issues.

Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.

Address: Top Floor, 111 Rathmines Road Lr, Dublin 6

Tel: 353 (01) 441 0024

GreenCross Publishing is owned by Graham Cooke.

The benefits of registering: only registered users:
  • receive the ecCopy two days prior to the printed edition.
  • have automatic access to our free CPD sites.
  • can partake in our online MCQs.
  • can enter our online sports quiz.

Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.

Download the new Mindo app for both IOS & Android.

  • Get notified when a story goes live
  • Access Premium Content
  • Read Offline
[the_ad_placement id="main-ldb-public"]
[the_ad_placement id="main-ldb-mobile-public"]

You are reading 1 of 2 free-access articles allowed for 30 days

HPRA advises pharmacists on outdated Epilim safety information

By Dermot - 19th May 2020 | 6 views

The Health Products Regulatory Authority (HPRA) has written to pharmacists warning that legacy batches of the drug sodium valproate (Epilim) still available in some pharmacies do not contain updated safety information.

In a recent letter, the HPRA highlighted several specific batches of the drug, some of which have expiry dates into 2021, that lack new advice in relation to pregnancy prevention, which was issued after a 2018 European Medicines Agency (EMA) review.

Epilim is used in the treatment of epilepsy and bipolar disorder. If a woman becomes pregnant while taking the drug, her baby is at risk of serious birth defects and developmental disorders.

In April 2018, pharmaceutical company Sanofi issued new contraindications, strengthened warnings and measures to prevent valproate exposure during pregnancy, as mandated by the EMA.

The safety information advised: “Valproate should not be used in female children, girls and women of childbearing potential unless other treatments are ineffective or not tolerated.”

The new advice led to changes to package leaflets, the inclusion of a pregnancy warning symbol on blister packs, and a pregnancy warning symbol and an updated text warning on the outer cartons.

The HPRA issued the notice to pharmacists recently to ensure that where batches with outdated leaflets were being given to women, that the most up-to-date package leaflet should be provided. 

“The HPRA is aware that there are some legacy batches of Epilim products remaining on the Irish market which, although released in compliance with the relevant marketing authorisations at the time, do not contain the updates required after the 2018 review. Some of these batches have expiry dates into late 2020 and early 2021,” the letter stated.

“The HPRA wishes to highlight the existence of these batches to pharmacists. This is so that pharmacists may take measures to ensure that any woman/girl of childbearing potential who is being dispensed Epilim receives the most up-to-date information about their medicine, specifically in relation to pregnancy prevention.”

Leave a Reply

[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]
Latest Issue
The Medical Independent – 24 June 2021

You need to be logged in to access this content. Please login or sign up using the links below.

[the_ad_placement id="main-mpu-public"]
Most Read
[the_ad_placement id="main-ldb-public-2"]
[the_ad_placement id="main-ldb-mobile-public-2"]